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http://dx.doi.org/10.1016/j.kjms.201Abstract The anticompulsive potential of agomelatine, a potent MT1/2 receptor agonist, and
its combined effect with m-chlorophenylpiperazine hydrochloride (mCPP), bicuculline, and
diazepam, were investigated in male C57BLJ/6 mice using marble-burying behavior (MBB) test.
Acute administration of agomelatine (30e40 mg/kg, intraperitoneal (i.p.)) significantly inhib-
ited the MBB in mice without influencing their locomotor activity. Further, chronic (28 days)
administration of lower doses of agomelatine (10 and 20 mg/kg, i.p.) dose-dependently
reduced the MBB without influencing their locomotor activity. Interaction studies revealed that
pretreatment with mCPP (0.5 mg/kg, i.p.), a serotonin 5HT2C agonist, partially attenuated the
anticompulsive effect of agomelatine (30 mg/kg). Further, a GABAA receptor agonist (diaz-
epam, 1.25 mg/kg, i.p.) and antagonist (bicuculline, 1 mg/kg, i.p.) had no influence on the
effects of agomelatine on MBB and locomotor activity. The doses of modulators were selected
on the basis of dose-response studies. The results indicate that agomelatine has a potent antic-
ompulsive effect that can be attributed to 5HT2C antagonism and MT1/2 agonism, and is
certainly not mediated via its effects on the GABAergic system. Thus, the study adds to thellege of Pharmacy, Postgraduate Research Department, Off Sinhgad Road, Vadgaon (Bk), Pune 41,
.com, psbhutada@live.com (P. Bhutada).
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Agomelatine in obsessiveecompulsive disorder 363growing literature on the psychopharmacological effects of agomelatine, and warrants further
exploration in multiple paradigms.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Suboptimal efficacy of anticompulsive drugs in patients
refractory to selective serotonin reuptake inhibitors (SSRIs)
remains a major obstacle to an optimal therapeutic
outcome in obsessiveecompulsive disorder (OCD). Thus,
novel strategies for the treatment of OCD are eminent.
Agomelatine is a new antidepressant with melatonergic
receptor agonist (MT1/2) and 5HT2C receptor antagonist
activity. Recent evidence indicates that it has a potent
anxiolytic and antidepressant effect in animal models as
well as in clinics [1]. It is also reported that OCD patients
exhibit normal circadian oscillations in plasma melatonin
concentrations, but lower plasma melatonin levels [2,3]. It
is noteworthy that a preliminary trial reported that
switching of OCD refractory patients from SSRIs to agome-
latine resulted in a marked reduction in symptoms;
however, the study involved only six patients [4]. Treat-
ment with agomelatine also resulted in a clinical improve-
ment in OCD refractory patients [5]. These recent clinical
outcomes indicate a potential use of agomelatine in the
treatment of OCD. No preclinical data exist on the modu-
lation of compulsive behavior by agomelatine, therefore in
order to increase the understanding on the anticompulsive
effect of agomelatine and to characterize its mode of
action the present study was planned involving the use of
marble-burying behavior (MBB) as a model to screen anti-
OCD like effects. C57BL/6 mice have been used previously
to study MBB [6,7].
MBB is an unconditioned specific defensive reaction in
rodents that is not associated with physical danger, and
does not habituate upon repeated testing [8,9]. In mice, it
is markedly attenuated by the acute administration of
SSRIs and tricyclic antidepressants [10], despite the acute
anxiogenic properties of these drugs [11,12]. The behavior
is reported to possess a good predictive validity and lately
considered to be a paradigm of OCD-like symptoms
[13,14], rather than anxiety [15,16]. In addition, to
eliminate false positives it is suggested that the effec-
tiveness of drugs is tested after repeated administration
[10]. Therefore, the influence of acute and chronic
administration of agomelatine on the MBB of mice was
studied. To determine the role of 5HT2C antagonism in the
anticompulsive effect of agomelatine, we studied the
interaction of agomelatine with m-chlorophenylpiper-
azine hydrochloride (mCPP), a 5HT2C agonist, in a MBB
test. In vitro and in vivo evidence also exists for inter-
action between melatonin and agomelatine with central
gamma-amino-butyric acid (GABA) neurotransmission
while influencing behavior [17]. Hence, we studied
the interaction of agomelatine with GABAA receptor
modulators.Experimental procedures
Animals
Adult male C57BL/6J mice (24e30 g) were used in the
present investigations. Mice were kept at 23  2 C under
12:12 hour light/dark cycle (light cycle: 08:00e20:00 h),
with free access to standard rodent diet and tap water.
Behavioral studies were carried out between 9:00 AM and
2:00 PM to minimize circadian influences (if any), in a noise-
free room. All the experiments were approved by the
Institutional Animal Ethics Committee, constituted for the
purpose of the control and supervision of experimental
animals by the Ministry of Environment and Forests,
Government of India, New Delhi, India.
Drugs and solutions
Bicuculline methiodide (Sigma-Aldrich, St. Louis, MO, USA)
and mCPP (Tocris Biosciences, London, UK) were dissolved
in 0.9% saline. The agomelatine and diazepam were a gift
from Cadila Pharmaceuticals Ltd, India, and SPARC, India,
respectively. Agomelatine was dissolved in hydroxyl-ethyl-
cellulose (1%) and diazepam was dissolved in one drop of
Tween 80 (0.5%) and diluted with saline [17].
Marble-burying behavior test
The MBB test was carried out as described earlier [8]. In
brief, 20 small glass marbles (w10 mm) were evenly spaced
in plastic cages (40  28  14 cm) in four rows and five
columns over 5-cm thick sawdust bedding. The cage was
covered by a transparent plastic lid with line markings
(3  2) and the apparatus was placed 2 m below a video
camera in the experiment room with luminance on the
surface of the test apparatus of 60 lux. The mice were
individually placed in a MBB apparatus with 20 glass
marbles for 30 minutes and the number of unburied marbles
was counted. The total number of marbles buried was
considered as an index of obsessiveecompulsive behavior.
Also, the total number of line crossings measured for the
duration of 30 minutes was considered as locomotor counts
for the animals.
Effects of acute treatment with agomelatine,
diazepam, and bicuculline on the marble-burying
behavior test in mice
Mice were randomly assigned to treatment conditions
(n Z 7) in which agomelatine (10, 20, 30, or 40 mg/kg,
364 P. Bhutada et al.i.p.), diazepam (0.625, 1.25, or 2.5 mg/kg, i.p.), bicu-
culline (1 or 2 mg/kg, i.p.), mCPP (0.25, 0.5 or 1.0 mg/
kg), or respective vehicles (10 ml/kg, i.p.) were admin-
istered immediately and 15 minutes after the mice were
subjected to the MBB test and the number of marbles
buried and locomotor counts were recorded for 30
minutes.Effects of chronic treatment with agomelatine on
the marble-burying behavior test in mice
Mice were randomly assigned to treatment conditions
(nZ 7) in which agomelatine (10, 20, 30, or 40 mg/kg, i.p.)
or a vehicle (10 ml/kg, i.p.) was administered daily for 28
days. On days 1, 7, 14, 21 and 28, 30 minutes after these
mice were subjected to the MBB test, the number of
marbles buried and locomotor counts were recorded.Mechanistic studies: co-administration with GABA
modulators and a 5HT modulator
There were three other groups of mice. In one,, the mice
were co-administered with a vehicle (10 ml/kg, i.p.), or
diazepam (1.25 mg/kg, i.p.) plus agomelatine (20 mg/kg,
i.p.). In another group, mice were co-administered with
bicuculline (1 mg/kg, i.p.) or a vehicle (10 ml/kg, i.p.)
plus agomelatine (30 mg/kg, i.p.), or a vehicle (10 ml/
kg, i.p.).
In the third separate group, mice were acutely co-
administered with mCPP (0.5 mg/kg, i.p.), vehicle
(10 ml/kg, i.p.) plus agomelatine (30 mg/kg, i.p.), or
vehicle (10 ml/kg, i.p.). Thirty minutes after administra-
tion, the mice in the various groups were individually sub-
jected to the MBB test and the number of marbles buried
and the locomotor counts were recorded for the next 30
minutes.Figure 1. Effects of acute treatment with agomelatine, m-chlor
culline on marble-burying behavior and locomotor activity in mice
peritoneal route with agomelatine (10, 20, 30, and 40 mg/kg), d
1.0 mg/kg), or bicuculline (1 and 2 mg/kg) and 30 minutes therea
represents the mean  standard error of the mean of seven to ni
vehicle treatment group (one-way ANOVA followed by Dunnett’s teStatistical analysis
The data obtained from the chronic study and co-
administration studies was analyzed using two-way anal-
ysis of variance (ANOVA) followed by Bonferroni multiple
comparisons post hoc test, while considering two factors,
i.e., treatment and time for chronic study, and agomelatine
treatment and modulator treatment for mechanistic
studies. Data from the acute administration studies were
analyzed with one-way ANOVA followed by Dunnett’s
multiple comparisons post hoc test. The results are
expressed as mean  standard deviation and a p value
<0.05 was considered to be statistically significant in post
hoc analysis.Results
Effects of acute treatment with agomelatine and
other agents on the marble-burying behavior test in
mice
One-way ANOVA revealed that the acute administration of
agomelatine [F (4, 34) Z 61.16, p < 0.0001]; diazepam [F
(3, 27)Z 20.26, p < 0.0001]; bicuculline [F (2, 20)Z 8.257,
pZ 0.0038]; and mCPP [F (3, 27)Z 8.987, pZ 0.0004] had
a significant influence on MBB in mice. Post-hoc analysis
revealed that the MBB was significantly reduced by ago-
melatine (30 and 40 mg/kg, p < 0.001) and diazepam
(2.5 mg/kg, p < 0.001), whereas it was significantly
increased by bicuculline (2 mg/kg, p < 0.05) and mCPP
(1 mg/kg, p < 0.05). Lower doses of all these agents had no
effects on the MBB (p > 0.05) (Fig. 1).
The administration of various doses of agomelatine had
no effect on locomotor activity; whereas treatment with
diazepam [F (3, 27) Z 51.29, p < 0.0001] and mCPP [F (3,
27) Z 3.771, p Z 0.0238] significantly affected locomotor
activity. Post-hoc analysis revealed that diazepamophenylpiperazine hydrochloride (mCPP), diazepam and bicu-
. Separate groups of mice were treated acutely via the intra-
iazepam (0.625, 1.25, and 2.5 mg/kg), mCPP (0.25, 0.5, and
fter subjected to a marble-burying behavior test. Each value
ne observations. *p < 0.05 and ***p < 0.001 versus respective
st).
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2.5 mg/kg dose, whereas mCPP significantly increased the
locomotor activity (p < 0.05) at a 1 mg/kg dose. The lower
doses of these agents had no effect on locomotor activity
(p > 0.05) (Fig. 1).
Effects of chronic treatment with agomelatine on
the marble-burying behavior test in mice
Two-way ANOVA revealed that the chronic administration
of agomelatine had a significant influence on the MBB of
mice. Analysis further revealed that agomelatine treatment
dose-dependently and time-dependently reduced the MBB,
with effects on treatment [F (4, 190)Z 211.5, p < 0.0001],
time [F (4, 190) Z 22.75, p < 0.0001], and treatment and
time interaction [F (16, 190) Z 4.646, p < 0.0001] (Fig. 2).
Post-hoc analysis revealed the onset of the inhibitory
influence of agomelatine (10, 20, and 30 and 40 mg/kg) was
from days 21, 7 and 1, respectively (p < 0.001). In general,
acute and chronic administration of agomelatine
(10e40 mg/kg) did not influence locomotor activity,
although the chronic administration of agomelatine (40 mg/
kg) slightly reduced the locomotor counts (Fig. 2).
Effects of acute treatment with
m-chlorophenylpiperazine hydrochloride,
diazepam or bicuculline on the influence of
agomelatine in the marble-burying behavior test
Two-way ANOVA revealed a significant mCPP treat-
menteagomelatine treatment interaction [F (1, 24)Z 10.36,Figure 2. The effects of chronic treatment with agomelatine
Separate groups of mice were treated with agomelatine (10, 20, 3
were subjected to a marble-burying behavior test on days 1, 7, 1
respective days (two-way ANOVA followed by Bonferroni test).p Z 0.0037], mCPP treatment effect [F (1, 24) Z 6.396,
p Z 0.0184] and agomelatine treatment effect [F (1,
24) Z 154.20, p < 0.0001]. None of these treatments had
a significant effect on motor activity (Fig. 3).
Further, two-way ANOVA revealed a non-significant
diazepam treatmenteagomelatine treatment interaction
[F (1, 24)Z 3.000, pZ 0.0961], diazepam treatment effect
[F (1, 24) Z 0.0374, p Z 0.8490] and agomelatine treat-
ment effect [F (1, 24) Z 0.1481, p Z 0.7031]. None of
these treatments had a significant effect on motor activity
(Fig. 3).
Two-way ANOVA also revealed a non-significant bicu-
culline treatmenteagomelatine treatment interaction [F
(1, 24) Z 0.09449, p Z 0.7612], bicuculline treatment
effect [F (1, 24) Z 1.512, p Z 0.2308] and agomelatine
treatment effect [F (1, 24)Z 387, p < 0.0001]. As with the
other analyses, these treatments had no significant effect
on motor activity (Fig. 3).Discussion
This study demonstrated that agomelatine, a melatonin
MT1/2 receptor agonist with 5HT2C receptor antagonistic
property, can modulate compulsive behavior on both acute
and chronic administration in mice.
The present study revealed that acute administration of
agomelatine (30e40 mg/kg, i.p.) reduced MBB. Further,
chronic administration of agomelatine (10 and 20 mg/kg,
i.p.) significantly and dose-dependently reduced the MBB.
These doses were found to be ineffective (or were below
the desired level of efficacy) on acute administration.on marble-burying behavior and locomotor activity in mice.
0, or 40 mg/kg). Thirty minutes after administration, the mice
4, 21, and 28. *p < 0.001 versus the vehicle-treated group on
Figure 3. The effects of acute treatment with mCPP, diazepam or bicuculline on the influence of agomelatine on marble-burying
behavior and locomotor activity in mice. Separate groups of mice were co-administered with mCPP (0.5 mg/kg), diazepam
(1.25 mg/kg) or bicuculline (1.0 mg/kg) prior to agomelatine (20 or 30 mg/kg), and subjected to a marble-burying behavior test.
***p < 0.001 versus respective agomelatine control group (two-way ANOVA followed by Bonferroni test).
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influenced locomotor activity. Thus, the present findings
suggest that agomelatine may have novel therapeutic
potential for the treatment of OCD-like symptoms.
The mechanism implicated in the observed influence of
agomelatine on MBB in mice appears pleotropic. The
evidence suggests that serotonin dysfunction has a primary
role in the obsessiveecompulsive behavior, and agomelatine
is reported to be an antagonist of the 5HT2C receptor.
Moreover, evidence suggests that there is an inhibitory
influence of selective 5HT2C receptor antagonism on MBB
[18]. Therefore, we studied the influence of mCPP (a 5HT2C
agonist) on the effect of agomelatine in the MBB test. The
results revealed that pretreatment with mCPP partly atten-
uated the inhibitory influence of agomelatine. This suggests
that modulation of the 5HT2C receptor by agomelatine may
be involved, partly, in the inhibitory effect on MBB.
Melatonin receptor agonists are reported to influence
the GABA neurotransmission and co-administration of sub-
effective doses of benzodiazepine receptor agonist and
agomelatine exhibits a weak anxiolytic-like effect in
various animal models of anxiety [17]. The results of the
present study revealed that co-administration of sub-
effective doses of diazepam and agomelatine had no effect
in MBB. This suggests that agomelatine may not involve the
modulation of GABAA receptors while influencing MBB. This
notion is further supported by the observation that bicu-
culline, a GABAA receptor antagonist, had no effect on the
inhibitory influence of agomelatine on MBB. In conclusion,
the results of the present investigation revealed that acute
as well as chronic administration of agomelatine attenu-
ated MBB in mice without influencing locomotor activity
suggesting the potential of melatonergic modulation in
OCD-like symptoms.References
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